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INTRODUCTION 
 Human Immunodeficiency Virus, the cause of AIDS, continues to 
spread, being described as a global health emergency by the world health 
organization. HIV type 1 is the etiologic agent of most cases of AIDS1,2. The 
epidemic of HIV-1 infection continues to expand globally, with more than 40 
million humans currently infected by the virus3. HIV disease has claimed 
more than 20 million lives worldwide4. The recent estimate done by National 
AIDS Control organization reports 5.1 million HIV infected people in India. 
 India has the second highest HIV / AIDS burden in the world next to 
south Africa. It is a disease that is acquired, for which no permanent cure has 
been found till date, and consequently has a great impact on the quality of life 
of a patient. HIV/AIDS infection results in a wide range of clinical 
consequences from asymptomatic carriage to life threatening opportunistic 
diseases. In persons infected with HIV, ongoing viral replication produces a 
sequential  decline in and ablation of cell mediated immunity, giving rise to 
diverse manifestations of opportunistic disease. The acquired immuno 
deficiency syndrome is the most advanced stage of this illness, in which the 
infected host can no longer control opportunistic organisms or malignancies, 
that rarely cause illness in immuno competent individuals. The interactions 
between the human immuno deficiency virus and the human immune system 
are extraordinarily complex, as evidenced by the highly variable rates of 
disease progression observed in HIV infected individuals.  
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HIV subverts  the immune system by infecting CD4+ T cells that 
normally orchestrate immune responses and by activating the immune system 
and inducing a cytokine milieu that the virus uses to its own replicative 
advantage. The discovery that certain  chemokine receptors function as HIV 
Co-receptors of HIV entry into target cells has expanded the scope of host 
factors that play a role in the pathogenesis of HIV-induced disease. The lack 
of recognizable correlates of protective immunity in HIV infection continues 
to hamper vaccine development and immunotherapeutic approaches. It 
remains unclear why the vast majority of HIV infected patients experience 
inexorable immunodeficiency and disease progression despite the presence of 
these robust antiviral immune responses. 
The progress that has been made to date in understanding the 
pathogenesis of HIV infection is unparalleled. The recent availability of 
effective combination antiretroviral therapy has had extraordinary clinical 
benefits for patients and has also provided important insights into the 
immunologic and virologic factors associated with control of HIV infection 
and disease progression. It is clear that HIV induces dysfunction of nearly all 
elements of the immune system and that the pathogenesis of HIV disease is 
multifactorial, causing CD4+ T cell depletion and dysfunction. And the 
prevalence and morbidity due to opportunistic infections can be controlled by 
improving the general  condition and immune status of the individual. 
 In this study the impact of antiretroviral therapy on CD4+ cell count 
was evaluated in patients suffering from HIV / AIDS at Govt. Kilpauk 
Medical College, Chennai. 
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AIM OF THE STUDY 
AIM: 
 The aim of the study which was conducted on patients attending 
antiretroviral therapy centre (ART Centre) of Govt. Kilpauk Medical College 
Hospital was to evaluate the impact of highly active antiretroviral therapy on 
CD4 T cell count. 
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REVIEW OF LITERATURE  
DEFINITION: 
 HIV belongs to the lentivirus group of the retrovirus family. There are 
at least two types, HIV - 1 and HIV - 2. AIDS definition has varied widely, 
the most widely used being the Centre for Disease Control (CDC) 
classification of 1993. Since 1993, the definition of AIDS has differed 
between USA and Europe. The USA definition includes individuals with CD4 
count below 200/µl or CD4 percentage of total lymphocyte count of <14 % in 
addition to the clinical classification based on the presence of  specific 
indicator diagnosis called as AIDS - defining conditions. In Europe, the 
definition remain based on the diagnoses of  specific clinical conditions with 
no inclusion of CD4 lymphocyte count. 
GENETIC ORGANIZATION OF HIV - 1 
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HIV-1 is an enveloped retrovirus with a plus - stranded ribonucleic 
acid (RNA) genome that contains genes for proteins with structural, 
enzymatic, and regulatory functions.  
PREVALENCE AND CLASSIFICATION: 
 The global epidemiologic pattern of human immuno deficiency virus 
has changed dramatically from North America and Western Europe to Sub-
Saharan Africa and Asia, that includes countries like Nigeria, Ethiopia, India, 
Russia and China. The disease has evolved into an epidemic of mainly 
heterosexual transmission, disproportionately affecting those most socially 
and economically vulnerable sections, resembling the 'classic' infectious 
diseases. It is estimated that one third of those currently living  with 
HIV/AIDS are between  of the ages of 15 and 24. In India, the epidemic 
seems to be following the so called  'type 4' pattern, where the epidemic shifts 
from the highest risk group (commercial sex workers, drug users) to bridge 
population (clients of sex workers, STD patients and partners of drug users) 
and then to general population. 
 Estimate at the national level is that there are about  5.1 million people 
suffering from HIV infection at the end of 2004. States such as Tamilnadu, 
Andhra Pradesh, Manipur, Maharashtra, Nagaland and Karnataka are 
reporting high levels of infection (between 1-2 percent in antenatal women). 
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CLASSIFICATION OF AIDS: 
1993 AIDS SURVEILLANCE CASE DEFINITION: 
 Bacterial infections, multiple or recurrent. 
 Candidiasis of bronchi, trachea, or lungs 
 Candidiasis, esophageal 
 Cervical cancer, invasive 
 Coccidioidomycosis, disseminated or extrapulmonary 
 Cryptococcosis, extrapulmonary 
 Cryptosporidiosis, chronic intestinal (>1 month's duration)  
 Cytomegalovirus disease (other than liver, spleen or nodes) 
 Cytomegalovirus retinitis (with loss of vision) 
 Encephalopathy, HIV related 
Herpes simplex, chronic ulcer (>1 month's duration) or bronchitis, 
pneumonitis, or esophagitis  
Histoplasmosis, disseminated or extrapulmonary 
Isosporiasis, chronic intestinal (>1 month's duration) 
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Kaposis sarcoma 
Lymphoid interstitial pneumonia and/or pulmonary lymphoid 
hyperplasia 
Lymphoma, Burkitt's (or equivalent term) 
Lymphoma, immunoblastic (or equivalent term) 
Lymphoma, primary of brain 
Mycobacterium tuberculosis, any site (pulmonary or extrapulmonary) 
Mycobacterium avium - intracellulare complex or Mycobacterium 
kansasii (disseminated or extrapulmonary) 
Pnemocystis jirovecii pneumonia 
Pneumonia, recurrent 
Progressive multifocal leukoencephalopathy 
Salmonella septicemia, recurrent 
Toxoplasmosis of brain 
Wasting syndrome of HIV infection 
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1993 REVISED CLASSIFICATION SYSTEM FOR HIV INFECTION 
AND EXPANDED AIDS SURVEILLANCE CASE DEFINITION FOR 
ADOLESCENTS AND ADULTS5 
CLINICAL CATEGORIES 
 A B C 
CD4+ T Cell 
Categories 
Asymptomatic, 
Acute (Primary) 
HIV, or PGL 
Symptomatic, 
Not A or C 
Conditions 
AIDS-
Indicator 
Conditions 
1. ≥500/µL A1 B1 C1 
2. 200-499/µL A2 B2 C2 
3. <200/µL AIDS 
indicator T-cell count 
A3 B3 C3 
 
 Clinical conditions in category C are listed in the 1993 Aids 
Surveillance Case Definition.  
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CLASSIFICATION OF HUMAN IMMUNODEFICIENCY VIRUS 
INFECTION (WHO CLINICAL STAGING SYSTEM) 
Clinical Stage 1 
Asymptomatic 
Persistent generalized Lymphadenopathy (PGL) 
Performance scale 1 : asymptomatic, normal activity 
Clinical Stage 2 
Weight loss, < 10% of body weight  
Minor mucocutaneous manifestations 
Herpes zoster, within the last 5 years 
Recurrent upper respiratory tract infections (e.g bacterial sinusitis) 
And/or performance scale 2 : symptomatic, normal activity 
Clinical stage 3 
Weight loss, >10% of body weight 
Unexplained chronic diarrhea, > 1 month 
Unexplained prolonged fever (intermittent or constant), >1 month 
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Oral candidiasis (thrush) 
Oral hairy leukoplakia 
Pulmonary tuberculosis, within the past year 
Severe bacterial infections (e.g pneumonia, pyomyositis) 
And/or performance scale 3 : bedridden, >50% of the day during the last 
month 
Clinical stage 4 
HIV wasting syndrome,  
Pneumocystis jirovecii pneumonia 
Toxoplasmosis of the brain 
Cryptosporidiosis with diarrhea, > 1 month 
Cryptococcosis, extrapulmonary 
Cytomegalovirus (CMV) disease of an organ other than liver, spleen, or 
lymph nodes  
Herpes simplex virus (HSV) infection, mucocutaneous >1 month, or visceral 
any duration. 
Progressive multifocal leukoencephalopathy (PML) 
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Any disseminated endemic mycosis (e.g histoplasmosis, coccidioidomycosis) 
Candidiasis of the esophagus, trachea, bronchi, or lungs  
Nontyphoid Salmonella septicemia 
Extrapulmonary tuberculosis 
Atypical mycobacteriosis, disseminated 
Lymphoma 
Kaposis' sarcoma (KS) 
HIV encephalopathy  
And/or performance scale 4 : bedridden, >50% of the day during the last 
month. 
MODES OF TRANSMISSION: 
 Worldwide, HIV infection is basically a sexually transmitted infection.  
Unprotected heterosexual intercourse accounts for the large majority of cases 
of HIV infection in the developing world. The low efficiency of penile 
vaginal intercourse for transmission of HIV has now been well documented 
especially for transmission from women to men. Factors that may enhance the 
efficiency of heterosexual transmission of HIV include higher viremia or 
more advanced immuno deficiency  in the infecting partner, anal intercourse, 
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sex during menses and presence of other Sexually Transmitted Diseases. Viral 
load of HIV has been shown to be the primary determinant of heterosexual 
transmission in HIV - discordant couples6. Other factors that may increase the 
risk of heterosexual transmission are traumatic sexual intercourse, cervical 
ectopy etc7. 
FACTORS INFLUENCING THE SPREAD OF THE HUMAN 
IMMUNODEFICENCY VIRUS: 
Sexual behaviour is undoubtedly the most important determinant of 
HIV spread. In general men have more partners than women. The behaviour 
of one's partner is as relevant for the risk of HIV infection as is one's own 
behaviour. Sexual practices in particular the frequency of anal intercourse, 
which is the most efficient mode of sexual transmission of HIV. Last, but not 
least, the rate of condom use plays a major role in the extent of HIV spread. 
NATURAL HISTORY OF HUMAN IMMUNODEFICIENCY VIRUS 
INFECTION: 
The clinical spectrum of HIV infection includes primary infection (the 
acute retroviral syndrome), asymptomatic infection, early symptomatic 
infection, and advanced immunodeficiency with opportunistic complications. 
Viral load or viremia is monitored by measurement of HIV RNA in 
plasma, and immunologic status is reflected in the absolute number of CD4. 
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Plasma viremia declines precipitously with antibody seroconversion and the 
development of an anti-HIV immune response usually reaching a steady-state 
level within 6 to 12 months8,9. 
In most untreated asymptomatic patients, the CD4 cell count declines 
gradually over several years. The slope of decline is a function of the plasma 
viral load. Plasma viremia increases, accompanied by a more rapid decline in 
CD4 cell count before the onset of symptomatic disease. As the viral load 
increases and CD4 cell count falls the risk of opportunistic infections, 
malignancies, wasting, neurologic complications, and death increases 
substantially. 
There is considerable variation in the progression of HIV disease, with 
some individuals progressing from infection to AIDS in less than 5 years10 
and so-called long-term nonprogressors remaining asymptomatic without 
treatment or evidence of immunologic decline for many years11,12. 
A number of laboratory tests have been correlated with progressive 
immunodeficiency, the development of AIDS and mortality. Taken together, 
however, the CD4 lymphocyte count and plasma viral load are the best 
prognostic markers for subsequent disease course in an HIV-infected 
individual. The CD4 lymphocyte count, a specific test for cellular 
immunocompetence, is a sensitive predictor of the development of 
symptomatic HIV infection and  AIDS in the near term as it reflects current 
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immunologic capacity13. Conversely the plasma viral load (HIV-1 RNA) is an 
extremely useful predictor of disease course over a more extended period of 
time and is strongly associated with the rate of subsequent CD4 cell count 
decline. A more rapid decline in CD4 count, faster clinical progression and 
decreased survival are all associated with a higher baseline viral load. 
Baseline plasma viral load was a stronger predictor of progression and 
mortality than CD4 count. 
In addition the average annual decline in the CD4 count of HIV 
infected men varied according to their initial viral load, decreasing by 36 CD4 
cells/year among men with baseline HIV-1 RNA less than 500 copies/mL, 
and by 77 CD4+ cells/year among men with baseline HIV-1 RNA greater than 
30,000 copies/mL14. Using the viral load and CD4+ count together, however, 
gives the best prognostic estimate of subsequent clinical course.  
Put in the context of HIV pathogenesis, the viral load measures the 
replicative rate of the infection and its destructive potential for the cellular 
immune system, and the CD4+ count gauges the extent of immune 
compromise and the present risk of opportunistic disease. Subsequent studies 
revealed that survival after diagnosis of AIDS was directly related to the CD4 
cell level at diagnosis. In most studies before the availability of combination  
antiretroviral therapy, median survival after the diagnosis of AIDS was 
estimated to be between 12 and 18 months15. The mean survival time after a 
CD4+ count of  200/mm3 was 38 to 40 months16,17. 
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Other markers of HIV disease progression that have been validated in 
clinical studies include the HIV p24 antigen, serum β2-microglobulin, 
neopterin, acid-labile interferon-α, anti-p24 antibody, and soluble CD8. These 
so-called surrogate markers are measures of either viral markers or host 
immune responses to HIV. Many of these measures do not provide prognostic 
information independent of the viral load.  However the heat-denatured p24 
antigen assay does provide prognostic information independent of HIV-1 
RNA and could also be used in lieu of viral load or CD4+ lymphocytes as a 
marker of subsequent disease progression18,19. 
Other low-cost predictors of disease progression include total 
lymphocyte count and hemoglobin20,21,22. The probability of a HIV- infected 
individual developing opportunistic disease is influenced by several factors. 
First, immunocompetence is a critical determinant of whether an infected 
individual can contain a potential pathogen. As discussed later, the CD4+ cell 
count appears to be the most clinically useful measure of host cellular 
immunocompetence and plays a central role in the staging of HIV disease. 
Second, exposure to potential pathogens is required before disease can result. 
Third, the relative virulence of the pathogen. 
Although the range of CD4+ cell counts for some conditions is broad, 
most patients with truly opportunistic infections had CD4+ counts less than 
100/mm3.  HIV-1 infection increases susceptibility to tuberculosis23. Malaria 
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is also endemic in increased frequency and severity in HIV-infected persons, 
particularly during pregnancy. 
Clinical findings may also predict disease progression in seropositive 
subjects. Oral candidiasis and oral hairy leukoplakia are early clinical markers 
of immunosuppression and herald the development of  AIDS in many 
patients24. Generalized lymphadenopathy is also a clinical marker of HIV 
infection but does not predict progression to AIDS. Most opportunistic 
diseases increase the risk of death independently of the CD4+ cell count25. 
 
NATURAL HISTORY OF HUMAN IMMUNODEFICIENCY  
VIRUS (HIV) 
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CLINICAL PRESENTATION OF HUMAN IMMUNODEFICIENCY 
VIRUS INFECTION: 
 HIV infection causes disease manifestations that include, an acute viral 
illness seen in the initial weeks of infection and associated with a high viral 
load and an intense host immune response, immunologically mediated process 
and opportunistic disease resulting from impaired host responses as the 
cellular immune system is damaged or ablated. 
 Potent antiretroviral therapy has added two new categories of clinical 
manifestations that may be commonly encountered in patients with HIV 
infection namely immune reconstitution syndromes with exacerbations of 
previously silent or adequately treated infections, especially mycobacterial 
infections, and a syndrome of   lipodystrophy with fat loss and redistribution, 
elevated serum triglycerides and cholesterol, and insulin resistance seen in 
patients receiving HAART, especially with protease inhibitors. 
CLINICAL FINDINGS: 
Acute Retroviral Syndrome 
 The initial manifestation of HIV infection in one half to two thirds of 
recently infected  individuals is a mononucleosis like illness referred to as the 
acute retroviral syndrome. The incidence of the acute retroviral syndrome is 
not  precisely known. Overall this syndrome is probably underreported. The 
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clinical features of the acute retroviral syndrome are nonspecific and variable. 
The onset of the illness ranges from 1 to 6 weeks after exposure to the virus 
but peaks at 3 weeks. Fever, sweats, malaise, myalgias, anorexia, nausea, 
diarrhea, and a nonexudative pharyngitis are prominent symptoms26. 
Physical examination frequently reveals cervical, occipital, or axillary 
lymphadenopathy, rash and less commonly hepatosplenomegaly. Their 
occurrence is probably due to the depression of the CD4+ cell count that 
generally accompanies acute HIV infection. 
Laboratory evaluation of patients with the syndrome reveals a reduced 
total lymphocyte count, elevated sedimentation rate, negative heterophile 
antibody test, and elevated transaminase and alkaline phosphatase levels26. 
 Initially,  the total lymphocyte count, including both CD4+ and CD8+ 
cells decreases with a normal ratio of CD4+  to CD8+ cells. Within several 
weeks, both the CD4+ and CD8+ cell populations begin  to increase. The rise 
in CD8+  cell numbers is relatively greater than that in CD4+ cells, and the 
CD4/CD8 ratio is inverted. In the weeks that follow, the CD8+ cell population 
increase  rather markedly because of HIV specific CD8+ Tlymphocytes. The 
ratio of  CD4+ to CD8+ cells usually remains inverted as the acute illness 
resolves (primarily because of excess numbers of CD8+ cells) 
 HIV p24  antigen may be detected in the serum and cerebrospinal fluid 
in  about 75% of patients with primary HIV infection within 2 weeks of 
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exposure. The most sensitive marker for acute HIV infection, however, is 
plasma HIV RNA, which is markedly elevated in most patients27. Typical 
RNA levels range from  105 to more than 106 copies/mL of plasma. High level 
viremia is virtually diagnostic of acute infection in the absence of anti-HIV 
antibodies. 
 There is increasing interest in treating acute HIV with combination 
antiretroviral therapy, as there is evidence that this may both lower the viral 
setpoint and lead to enhanced CD4+  and CD8+  HIV-specific responses28. 
However early treatment does not appear to  prevent establishment of 
reservoirs of latently infected resting CD4+ cells and may not provide any 
long term benefit29.  
HIV INFECTION PROFILE 
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PERSISTENT GENERALIZED LYMPHADENOPATHY: 
 The pathogenesis of generalized lymphadenopathy is related to the 
rapid infection of CD4+ cells in lymph nodes by HIV after initial infection. 
The syndrome of PGL is defined as the presence of two or more extrainguinal 
sites of lymphadenopathy for a minimum of 3 to 6 months for which no other 
explanation can be found.  The most frequently involved node groups are the 
posterior and anterior cervical, submandibular, occipital, and axillary chains. 
Epitrochlear and femoral nodes may also be enlarged. Physical examination 
usually reveals symmetrical, mobile, rubbery lymph nodes ranging from  
0.5 to 2 cm. Pain and tenderness are uncommon. Mediastinal and hilar 
adenopathy is not characteristic of the syndrome. 
The natural history of HIV infection in individuals with PGL does not 
differ significantly from that of HIV infection without PGL. In patients 
treated  with HAART, previously involuted lymph nodes may again enlarge 
as HIV-specific and other T cells are replenished. In addition, focal 
lymphadenitis with constitutional symptoms may occur in patients with 
previously silent mycobacterial infections, 1 to 2 months after starting 
HAART. These 'reversal reactions' or immune reconstitution syndromes are 
reminiscent of reversal reactions seen in multibacillary forms of leprosy, 
heralding a return of pathogen specific T-cell responses. 
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CONSTITUTIONAL DISEASE AND WASTING: 
Severe wasting with loss of more than 10% of body weight is generally 
a finding of advanced HIV disease. The exact incidence of constitutional 
symptoms, fatigue, and weight loss is not known, and the etiology is varied 
and often multifactorial. Elevated levels of myostatin-immunoreactive 
protein, a muscle catabolic agent, have been found in men with HIV and 
wasting30. Weight loss has remained an important  predictor of mortality even 
in the era of HAART31. In patients with more advanced HIV disease with 
high viral loads and severe depletion of CD4+ cells, constitutional disease 
(fatigue, weight loss, malaise, fever) usually heralds the onset of  
opportunistic infections or malignancies. 
The definition of wasting syndrome in the United States is the presence 
of unexplained constitutional disease for more than 1 month with a 
temperature greater than 38.3oC, diarrhea, and loss of more than 10% of 
baseline body weight. 
IMMUNE RECONSTITUTION SYNDROMES: 
HAART (regimens that include a HIV protease inhibitor or non 
nucleoside reverse transciptase inhibitor together with nucleoside reverse 
transciptase inhibitors) is associated with dramatic reductions in HIV-1 RNA 
and increase in CD4 lymphocyte counts. They are sometimes associated with 
paradoxical worsening of underlying opportunistic infections32. Not every 
 22
patient who has immunologic improvement with antiretroviral therapy 
experience paradoxical worsening. But it has been noted in Mycobacterium 
tuberculosis, Mycobacterium avium Complex Disease, Cytomegalovirus, 
Varicella-Zoster virus,  Viral Hepatitis. 
THE IMMUNOLOGY OF HUMAN IMMUNODEFICIENCY  
VIRUS INFECTION: 
 HIV subverts the immune system by infecting CD4+ T cells. It is clear 
that HIV induces dysfunction of nearly all elements of the immune system 
and that the pathogenesis of HIV disease is multifactorial33. 
HUMAN IMMUNODEFICIENCY VIRUS ENTRY: 
CD4 was identified as the major cellular receptor for HIV fusion and 
entry in 198434. Transfection of the CD4 gene into CD-4 negative (CD-4) 
human cells rendered them infectable with HIV35. However, transfection of 
the human CD4 gene into murine cell lines did not render these cells 
susceptible to HIV infection despite glycoprotein (gp) 120 binding to CD4, 
suggesting that other factors were necessary for HIV fusion and entry.  The 
protein, called fusin, together with CD4, was required for T-tropic envelope 
fusion to target cells. 
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DISSEMINATION OF HUMAN IMMUNODEFICIENCY VIRUS 
INFECTION: 
  It remains unclear which cell type in the blood, lymphoid tissue, 
spleen, or mucosa is the first to actually become infected with HIV. However 
in studies of macaques exposed to SIV intravaginally, bone marrow-derived 
dendritic cells (DCs) in the vaginal mucosa are the first cells to contain SIV 
DNA which is detectable 2 days after exposure. 
 Recently, it has been shown that dendritic cell-specific intracellular 
adhesion molecule (ICAM) 3-grabbing nonintegrin (DC-SIGN)36,37, a protein 
expressed on DCs in the T-cell area of tonsils, lymph nodes, spleen and in the 
lamina propria of mucosal tissues, may be important in the attachment of HIV 
to DCs and may be an important factor in the transmission of HIV from DCs 
to T cells. It is likely that DCs carry HIV from tissues in which the initial 
rounds of viral replication occur to the regional lymph nodes, where CD4+ T 
cells become infected after contact with DCs. This leads to subsequent  
rounds of virus replication and spread in the absence of HIV-specific immune 
responses. Thus, lymphoid tissue plays a key role in the initiation and 
dissemination of HIV infection. 
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HUMORAL IMMUNE RESPONSES: 
 Antibodies that bind HIV proteins, including the viral surface envelope 
glycoprotein, can be detected in the plasma within weeks of HIV infection 
coincident with the decline of plasma viremia38,39.  
 Both the CD4 and co-receptor binding sites are well conserved among 
known viral isolates and are not glycosylated. For these reasons they are  
thought to be important targets of neutralizing antibodies.  
CELLULAR IMMUNE RESPONSES: 
Cytotoxic T-Lymphocytes  
MHC class I-restricted, HIV-specific CD8+ cytotoxic T-lymphocyte 
(CTL) responses are found in the peripheral blood within the first few months 
of HIV infection and are detected during the chronic phase of infection in the 
majority of HIV infected individuals40. First the temporal association of the 
peak of the HIV-specific CTL response with the decline of viremia during 
acute infections is thought to represent the effect of virus-specific CTL in 
restricting HIV replication in humans40,41. HIV-specific CD8+ T cells falls due 
to a lack of CD-4+ T-cell help42.  
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CD-4+ T-Cell Responses  
 Unlike most other infections of humans, HIV infection is characterized 
by the absence of HIV-specific CD4+ T-cell proliferative responses in the vast 
majority of untreated patients43. Because HIV infects CD4+ T-cell, it was 
believed that the early loss of HIV-specific proliferative responses may be the 
result of infection and deletion of HIV-specific CD4+ T cells in the lymphoid 
tissues on encountering the virus. Thus, there is now general agreement that 
HIV-specific CD4+ T cells persist in patients with progressive disease.  
RESERVOIRS OF HUMAN IMMUNODEFICIENCY VIRUS 
INFECTION: 
 There is unequivocal evidence from several lines of investigation that 
there is ongoing HIV replication despite effective ART. The most powerful 
demonstration of the inability of ART to eradicate HIV infection comes from 
in vivo studies of individuals who began ART during the chronic stage of 
HIV infection, achieved and maintained suppression of plasma HIV RNA for 
up to 2 years and subsequently interrupted therapy. Interruption of ART 
resulted in a rapid rebound of plasma viremia in 95% of individuals44. It has 
been demonstrated that an evolution in HIV envelope and protease genes 
occurs in individuals who have been effectively treated with ART, indicating 
persistent HIV replication despite adequate therapy45. Finally it has been 
demonstrated using ultrasensitive assays with a limit of detection of less than 
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3 copies/mL that many individuals with "undetectable" (<50 copies/mL) 
plasma HIV by standard assays have persistent low-level plasma viremia46.  
Thus there are reservoirs of ongoing HIV replication that persist in the 
presence of effective ART. Important HIV reservoir sites include lymphoid 
tissue and resting CD4+ T cells that circulate in the blood. 
RESTING CD4 T CELLS: 
It has been clearly demonstrated that the pool of resting CD4+ T cells 
that carry replication-competent HIV persisted in essentially all infected 
individuals who  were receiving ART29, 47,48. This HIV reservoir is established 
during the earliest stages of HIV infection. The initiation of ART as early as 
10 days following infection with HIV does not prevent the establishment of 
the resting CD4+ T-cell reservoir of HIV. Therefore, the pool of HIV-infected 
resting CD4+ T cells is a clinically relevant reservoir of HIV. 
LYMPHOID TISSUE: 
 Lymphoid tissue is a major site of HIV replication and plays a role in 
the progression of disease throughout all stages of  infection. The significant 
role of lymphoid tissue in ongoing HIV replication during all stages of disease 
in the absence of ART suggests that this compartment may play a significant 
role in ongoing HIV replication in the presence of ART. There is a rapid 
decrease in lymph node viral burden following the initiation of ART,  
within 24 weeks, the majority of HIV RNA detected by in situ  
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hybridization is eliminated and it is uncommon to detect HIV RNA in the 
germinal centers49. There is a commensurate decrease in HIV RNA as 
quantified by reverse transcription - polymerase chain reaction per gram of 
tissue or in isolated lymph node mononuclear cells. Lymphoid tissue other 
than lymph nodes may serve as important reservoirs of HIV infection. 
Gastrointestinal lymphoid tissue harbors HIV that is not completely cleared 
with  ART. However, the precise contribution of non-lymph node lymphoid 
tissue to persistent HIV replication in the presence of ART remains unknown. 
MECHANISMS OF CD4+ T-CELL DEPLETION : 
 Effective ART has provided fundamental insights into the 
understanding of the potential contributions of increased destruction, 
decreased production, and redistribution as mechanisms for CD4+ T-cell 
depletion in HIV-infected individuals. 
a)   Increased Destruction 
1. Direct Infection :  The observations that CD4+ T cells are the principal 
targets of HIV infection in vivo34 and that HIV infection of CD4+ T cells 
in vitro causes cytopathicity50,51 led to a reasonable assumption that direct 
infection of CD4+ T cells in vivo results in their depletion.  However 
quantitative studies of the frequency of HIV infected cells in vivo suggest 
that single cell killing by direct infection with HIV may not be the 
predominant mechanism of CD4+ T cell depletion. 
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2. Apoptosis :  Apoptotic cell death is characterized by plasma 
membrane blebbing, nuclear condensation, DNA fragmentation and 
release of cellular contents in the form of small, dense apoptotic 
bodies. Ingestion of apoptotic bodies by phagocytes completes the 
apoptotic death process without the inflammation associated with 
spillage of cellular contents that occurs in nonphysiologic necrotic cell 
death. Perhaps the most compelling evidence that apoptosis may play a 
role in HIV pathogenesis is that an increased frequency of apoptosis in 
CD4+ T cells is seen in HIV infected humans52.  
3. Autoimmune phenomena : may contribute to CD4+ T cells depletion 
in HIV infected individuals.  
4. Bystander Phenomena :  HIV-uninfected cells as a contributory 
mechanism to the loss of CD4+ T cells during the course of infection. 
b. Decreased Production 
 Decreased production of CD4+ T cells could occur by disruption of the 
thymic microenvironment53 and by HIV induced depletion of thymocytes. 
c. Redistribution 
Data from HIV infections indicate that there is significant trafficking 
of CD4+ T cells from the peripheral blood to lymphoid tissue in acute and 
chronic infection54. 
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CD8+ T Cells 
Dysregulation of CD8+ T cell numbers and function is evident through 
out the course of HIV disease. After acute primary infection, CD8+ T cell 
counts usually rebound to supranormal levels and may remain elevated for 
prolonged periods. Increases in CD8+ T cells during all but the late stages of 
disease may in part reflect the expansion of HIV - specific CD8+ cytotoxic T 
lymphocytes. In addition to cytotoxic T lymphocyte activity, other CD8+ T 
cell functions are impaired during HIV disease progression, including loss of 
noncytolytic non-MHC restricted CD8+ T cell derived HIV suppression. 
B - lymphocytes : 
Dysregulation of B - cell activation and the decreased ability of these 
cells to respond to antigen are likely responsible in part for the increase in 
certain bacterial infections seen in advanced HIV disease in adults. The 
number of circulating B cells may be decreased in primary HIV infection, 
However this is usually a transient phenomenon and likely reflects, at least in 
part, a redistribution of cells into lymphoid tissues. Soon after the resolution 
of acute HIV infection, hypergammaglobulinemia and B - lymphocyte 
hyperactivation are noted. The increase in immunoglobulins occurs for all 
classes of antibody. 
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NATURAL KILLER CELLS 
 Abnormalities of NK cells are observed throughout the course of HIV 
disease and these abnormalities increase with disease progression. Most 
studies report that NK cells are normal in numbers and phenotype in HIV-
infected individuals. However, decreases in numbers of the CD16+/CD56+ 
subpopulation of NK cells with an associated increases in activation markers 
have been reported55. NK cells from HIV-infected individuals are defective in 
their ability to kill typical NK target cells as well as gp 160-expressing cells. 
In addition, it has recently been demonstrated that HIV viremia is inversely 
correlated with the ability of NK cells and NK-derived cell supernatants to 
suppress virus replication. Thus, NK cells, like CD8+ T cells, may inhibit HIV 
replication by cell-mediated killing, as well as by secretion of soluble HIV 
inhibitory factors.  
NEUTROPHILS 
 Dysregulation of neutrophil function occurs at all stages of HIV-
infection. The oxidative capacity of neutrophils after priming with 
granulocyte macrophage colony-stimulating factor is also increased in HIV-
infected individuals. The opsonizing activity of neutrophils is significantly 
impaired in HIV infection and the degree of impairment correlates with 
disease progression.   
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MONOCYTE - MACROPHAGES 
 Cells of the monocyte-macrophage lineage play key roles in the 
immunopathogenesis of HIV disease. These cells serve as reservoirs of viral 
infection and are responsible for a variety of tissue-specific pathologic 
processes. Dysfunction of these cells contributes to CD4+ T cell dysfunction 
and to impaired host defense against intracellular pathogens33. These cells are 
central to the pathogenesis of HIV-induced central nervous system disease. 
As a consequence of these HIV-induced functional abnormalities, monocyte-
macrophages exhibit poor intracellular killing of Histoplasma capsulatum56 
and others.  
DENDRITIC CELLS 
 Dendritic Cells  are among the first cells to encounter HIV after 
mucosal exposure and  are probably responsible for transporting the virus to 
lymphoid organs thus facilitating infection of CD4+ T cells and viral 
dissemination.  
HIGHLY ACTIVE ANTIRETROVIRAL TREATMENT: 
 Studies of HIV kinetics showed rapid replication of HIV throughout 
the course of the illness, and 99% of viral production is from recently infected 
cells. And the average patient, in the absence of treatment, progresses to 
AIDS defining diagnosis during 9-10 years after viral transmission and has an 
average viral burden of 104 to 105 copies / mL. The increasing availability of 
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superior combination of drugs reduces  viral burden, CD4+ Cell slope (the rate 
of decline of the number of CD4+ cells) and rates of progression. 
The commonly used combinations are usually among Nucleoside 
Analogs like Zidovudine, Didanosine, Zalcitabine, Stavudine, lamivudine, 
Abacavir, Tenofovir and among Nonnucleoside reverse transcriptase 
inhibitors like Nevirapine, Delavirdine, Efavirenz and among protease 
inhibitors like Indinavir, Ritonavir, Saquinavir, Nelfinavir, Amprenavir, 
Lopinavir. 
The HAART treatment required atleast 3 drugs to achieve maximum 
viral suppression but adherence was challenging and critical57,58. Despite 
hundreds of studies with thousand of patients, there was no evidence of long-
term benefit with therapy started  before the CD4 count was 200 / mm3. There 
were large cohort studies that showed that treatment initiated with a CD4 
count of less than 200 / mm3 was beneficial and possibly too late. The result 
of these observations is the recommendation to start therapy  when the CD4 
count is 350 / mm3 but the current NACO guidelines recommend the 
threshold of 200 / mm3. 
WHAT TO START: 
 Once the decision is made to initiate treatment, the regimen used 
should provide maximum viral suppression. This is best achieved with one of 
the following59,60. Generally recommended combination are Two nucleosides 
and a Protease Inhibitors, Two nucleosides and an NNRTI, Two nucleosides 
and two Protease Inhibitors. 
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WHEN TO CHANGE: 
 The goal is maximal viral suppression, which is generally defined as a 
viral load of less than 20 to 50 copies / mL after at least 6 months of 
treatment. The rationale for this goal is that maximal viral suppression means 
minimal viral replication with evolution of resistance mutations. Nevertheless, 
it should be acknowledged that (a) opportunistic infections are infrequent with 
viral loads less than 5,000 copies / mL61, (b) the threshold for risk of 
resistance is unclear62,63, (c) there is benefit to treatment even in the absence 
of a demonstrable antiviral effect attributed to viral fitness64, (d) for many 
patients the goal of a viral load of less than 20 to 50 copies / mL is unrealistic, 
so changes based on this threshold could result in the rapid loss of therapeutic 
options65. The conclusion is that the goal of therapy should ideally be "no 
detectable virus" using an assay with a threshold of 20 to 50 copies / mL, but 
that several additional considerations include the need to preserve therapeutic 
options and the benefit of partial suppression66.  
MONITORING: 
 The major method to determine response to therapy is sequential viral 
load measurements. Expectations with HAART for treatment-naive patients is 
a viral load decrease of 1 to 2 log10 copies / mL at 1 to 2 months, viral load 
less than 400 copies / mL at 12 weeks, and less than 50 copies / mL at 16 to 
24 weeks66. The CD4 count is another method to monitor response to therapy 
and is the most critical measurement for determining vulnerability to HIV-
associated complications. In general the average increase  in CD4 count with 
complete viral suppression is 80 to 100 cells / mm3 per year. Discordance in 
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the CD4 cell response and the viral load response is seen in up to 30% of 
patients, about 15% showing a CD4 response with minimal viral response, 
and 15% showing a good virologic response with no CD4 response67. 
THE IMPACT OF HAART ON THE CLINICAL MANIFESTATIONS 
OF HUMAN IMMUNODEFICIENCY VIRUS : 
 Changes in plasma viral and CD4+ cell counts resulting from 
antiretroviral drug treatment have been shown to be strong predictors of 
clinical progression (or regression) of HIV disease68,69. A study from 
Switzerland indicates that patients receiving effective antiretroviral treatment 
have a risk of death that is similar to that in patients with cured cancer70. 
 Effective therapy has not only decreased the incidence of new 
opportunistic infections but also led to resolution of preexisting conditions; 
HAART represent atleast a partial immune reconstitution, although the 
recovery of antigen-specific immunity appears to lag behind CD4+ cell count 
increases71,72,73,74. The incidence of new opportunistic infections in patients 
who have had satisfactory virologic and immunologic responses to HAART is 
extremely low, even when primary prophylaxis has been discontinued75,76. 
The clinical course of HIV disease in individuals receiving combination 
antiretroviral therapy is likely to evolve further in the coming years. 
 35
PATIENTS AND METHODS  
 Patients who are confirmed to have HIV/AIDS and attending the ART 
CLINIC were taken up for the study in the period between  December 2005 to 
September 2006. Only adults above the age of 12  years among both males 
and females were selected. Total of 58 number of patients were analysed. 
INCLUSION CRITERIA: 
¾ All confirmed HIV/AIDS patients whose CD4 cell count was less than 
200/µl were only taken up for highly active antiretroviral therapy. 
¾ Patient above the age of 12 years. 
EXCLUSION CRITERIA: 
¾ Patients  who were confirmed as HIV/AIDS positive patients whose CD4 
cell count was more than 200 / µl were excluded from the study.  
¾ Pt who were in the pediatric age group of less than 12 years were also 
excluded. 
In this study, patients irrespective of the clinical stage, whose CD4 count 
was less than 200 / µl were started on HAART. 
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CONFIRMATION OF HIV/AIDS   
Screening: 
 All patients who had high risk behaviour were screened. High risk 
behaviour was defined as premarital sex / Extramarital sex / Multiple partners / 
Tuberculosis / Intravenous Drug Abuse /  Men having Sex with Men / 
Commercial Sex Workers were screened and confirmed in a three stage process. 
Stage I:  (HIV 1+2 Immunodot Test Kit) Dot immunoassay employs 
the same principle as Enzyme immunoassay whereby the immobilised antigen 
antibody complex is visualized by means of colour producing (chromogenic) 
reaction. 
PROCEDURE: 
 All kit components and samples to be tested should be brought to room 
temperature before starting the test. Add 2 drops (o.1ml) into micro test wells 
and diluted. 
 Antigen coated comb is labeled and incubated in diluted samples  
for 10 min. 
 Wash solution concentrate is diluted  
 Comb is washed to remove unbound proteins. 
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 Comb is incubated for 10 min at room temperature. 
 Then comb is washed with wash buffers. 
 Results are read visually and a magenta red spot is a positive indication 
of HIV 1/ and or 2 antibodies in the sample. 
STAGE 2/3: 
If stage 1 is positive, than a colloidal gold enhanced rapid immuno 
chromotographic assay for the qualitative detection of antibodies was done. 
PROCEDURE : 
 Bring all reagent and specimens to room temperature.  
Dispense 3 drops (100 µl) of the specimen or control into the sample 
well on the card. 
Interpret in 15 mts. 
The appearing of  T1 test line indicates HIV 1 positive result. 
The appearing of T2 test line indicates HIV 2 positive result. 
The appearance of Both test lines indicates both HIV 1 and 2 as 
positive. 
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 And another spot test to detect HIV 1 & 2 antibodies in plasma / serum 
is done to detect the bound antibodies. They are visualised by reacting with 
protein A Gold conjugate which binds to the HIV antibodies giving a distinct 
red spot.  If two red spot appears, the specimen was taken as positive.  
 If both the 2nd and 3rd test were positive, the case was confirmed as  
HIV positive. 
CD4 COUNT ASSAY: 
 Blood was collected in heparinized bottles for flow cytometry analysis.  
Blood was drawn in the morning and heparinized and was sent to Madras 
Medical College for analysis of CD3, CD4 and CD8 counts by flow 
cytometry. Flow cytometry is used in the phenotyping of T cell subsets  
for monitoring  of  HIV pts77.   
PROCEDURE: 
The Heparinized blood of about 100 µl of whole  blood is 
simultaneously stained and analysed for CD3, CD4 and CD878 by FACS 
Count Cytometry using LASER.  
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RESULTS 
Total number of 58 patients were analysed. Both the initial CD4 count 
and CD4 count after 6 months of highly active antiretroviral therapy were 
obtained as follows: 
TABLE - 1: AGE DISTRIBUTION - ANALYSIS  
Age Group No of Cases Percentage 
< 30 y 9 15.52 
31-40 y 36 62.07 
41-50 y 9 15.52 
51-60 y 4 06.90 
 
Mean ± SD  
37.03448 ± 6.965996 
Interpretation: 
 Among the 58 patients studied the age incidence was highest in the 
31-40 year age group (62-07%). This was followed by 15.52% in both under 
30 and between 41-50 years age group.  
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TABLE - 2:  SEX DISTRIBUTION – ANALYSIS 
 
Sex No of Cases % 
Male 39 67.24 
Female 18 31.03 
Transgender 1 1.72 
Total 58 100  
 
Interpretation: 
 Among the 58 patients studied the males where more commonly 
affected (67.24%) when compared to females 31.03% and transgender of 
(1.72%). 
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TABLE - 3: MODE OF SPREAD 
Mode No of Cases % 
Heterosexual (1) 53 91.38 
Intravenous Drug abuse (2) 2 3.45 
Commercial sex workers (3) 1 1.72 
Men having sex with men (4) 2 3.45 
Total 58 100 
 
Interpretation: 
 Among the 58 patients analysed it is the heterosexual transmission that 
is most common mode of transmission (91.38%), With men having sex with 
men constituting 3.45% and intravenous drug abuse constituting 3.45% and 
commercial sex workers constituting 1.72%. 
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TABLE - 4: ALCOHOLISM - CORRELATION  
TO SEXUAL BEHAVIOUR 
 
History of Alcohol Intake No of Cases % 
Yes 32 55.17 
No  26 44.83 
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TABLE - 5: SMOKING - CORRELATION TO SEXUAL BEHAVIOUR 
History of Smoking No of Cases % 
Yes 26 44.83 
No  32 55.17 
 
Interpretation: 
 Among the 58 patients studied 32 cases (55.17%) have history of 
Alcohol intake and 26 cases have history of smoking. Overall 18 patients out 
of 58 patients were both alcoholic and smoker. So it seems that smoking and 
alcohol influence sexual behaviour.  
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TABLE: 6 - INCOME ANALYSIS 
Group No of Cases % 
Group I (<1500 Rs.) 28 48.28 
Group II (1500 – 2500 Rs.) 27 46.55 
Group III (>2500 Rs.) 3 5.17 
Total 58 100 
 
Interpretation  
 
 Among the 58 patients studied 94.83% of the patients were earning 
lessthan Rs.2500 per month. So its seems that lower socio economic status is 
playing a role in altering sexual behaviour patterns. But this could also be 
because of a sampling bias, as most people who come to Government 
Hospital are poor patients.  
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TABLE - 7: ASSOCIATED ILLNESS / DISEASE 
Group Associated Illness No of Cases % 
1. Yes 6 10.34 % 
2. No 52 89.66 % 
 
TABLE - 8: DISEASE CONFIGURATION [ N = 6] 
Disease No of Cases % 
Pul.TB 4 66.67 
Extrapul.TB 1 16.67 
Jaundice 1 16.67 
Total  6 100 
 
Interpretation: 
 Among the 58 patients studied, 6 patients had co-existing illness. 
Pulmonary tuberculosis was present in 4 patients, extra pulmonary 
tuberculosis in one patient and jaundice in one patient. So tuberculosis was 
the most common opportunistic infection in the study population. The 
associated illness was diagnosed at the time of the initial diagnosis of HIV 
and no patient developed any opportunistic infection during HAART so its 
seems HAART decreases the incidence of opportunistic infections.  
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TABLE - 9: BMI COMPARISON [ N = 58] 
 
BMI Mean ± SD 
Pre HAART BMI 18.84483 ± 2.867248 
During HAART BMI (after 6 months ART) 20.77586 ± 3.068191 
 
Interpretation  
 
 Among the 58 patients when the initial BMI was analysed it showed a  
mean BMI of 18.84483 ± 2.867248, which showed the high incidence of 
wasting in the HIV/AIDS patients. The follow up BMI showed a mean BMI 
of 20.77586 ± 3.068191%. When analysed for the statistical significance 
using paired 't' test its showed 'p' value of 0.000660, which seems to show that 
BMI also improved by HAART.  
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TABLE - 10: CD4 COUNT ANALYSIS [N = 58] 
  
 Pre HAART CD4 
Count 
No of Patients Percentage 
Group I 0 - 99 17 29.31 
Group II 100 - 149 16 27.59 
Group III 150 - 199 25 43.10 
Total   58 100 
 
Interpretation  
  
 Among the 58 patients, the maximum no. of patients who were started 
on HAART had a CD4 count between 150-199 (43.10%) followed by 17 
patients in Group I having CD4 count between 0-99 (29.31%) followed by 16 
patients in Group II having CD4 count between 100-149 (27.59%). 
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TABLE - 11: CD4 CELL COUNT COMPARISON [N = 27] 
CD4  Cell  Count Mean  ± SD 
Pre HAART CD4 127.4444 ± 53.08218 
During HAART CD4 (after 6 months follow up) 332.1482 ± 158.08 
 
Interpretation  
 Among the 27 patients analysed for the impact of HAART on CD4, the  
mean increase of 205 cells / mm3 was noted after six months of HAART, 
which was also statistically significant when analysed by paired 't' test which 
showed the 'P' value of 0.0000. 
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DISCUSSION  
 
 HIV/AIDS is an evolving health problem world wide, with more than 
40 million people already infected3.  
 It is important to view untreated HIV infection as a chronic ultimately 
fatal process that is punctuated by various manifestations,  which are 
influenced by multiple factors like route of HIV infection, size of inoculum, 
gender, medical intervention etc. In  India it is commonly acquired through 
Heterosexual contact. In the study the most common mode of transmission 
was found to be heterosexual with 91.38% acquiring the disease through this 
route. 
Once acquiring the infection, one to 6 weeks later patients experience a 
nonspecific illness called as "acute retroviral syndrome"26. During this 
episode, counts of total lymphocyte (both CD4 and CD8) characteristically 
fall, followed by an increase of CD879. CD4 count have been reported to be 
between 244 - 1055 cell / mm3 in one review within the first 4 weeks after 
acquisition of HIV80. CD4 count may recover for some patients but most 
patients demonstrate a decrease of 100 to 200 cells in the first 6 months after 
seroconversion and a decline of an additional 100 cells in the next 6 months.  
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In one review of 318 seroconverters  mean CD4+ cell count in the 
initial 12 month after seroconversion fell from 999 to 673/ mm81. In this study 
the mean initial CD4 count of all 58 patients who were started on HAART 
was 130 cells / mm3 ± 53.95. 
Studies suggest that early intervention with HAART can slow the 
decline of CD4 and reduce the no of clinical events during the initial several 
years of infection79,82. Barring one patient who died during the study no 
patient developed any clinical illness during the study period. And the natural 
history of illness have been dramatically altered by HAART. The likelihood 
of an initial AIDS defining condition developing in an untreated person who 
is HIV positive average about 4 to 10 percent per year after acquisition of 
HIV infection83. 
In terms of laboratory parameters the absolute peripheral CD4 
lymphocyte count and percentage of peripheral cells that are CD4+, both 
correlate with the likelihood of development of AIDS. And also retrospective 
and prospective studies show that lower the absolute CD4 count more likely is 
the patient to develop opportunistic infections like Cytomegalovirus, 
Pneumocystis Carinii pneumonia. Hence the relationship of the CD4 count to 
the  development of opportunistic infectious complications of HIV is 
important in approaching the management of HIV infection. 
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First, HIV infection implies that unless an effective therapeutic 
intervention is administered the immune function inexonerably declines  and 
infectious complication occur. Second, the monitoring of the immunologic 
decline primes the clinician to do the measures in anticipation of the 
complication. Third the immunologic state as measured by CD4 cell count 
provides guidance regarding the benefit of HAART. When the CD4 count 
falls below 200 cells /µl, effective HAART can clearly improve survival. At 
higher levels, HAART may improve survival. Fourth, a rise of CD4 in 
response to HAART predicts clinical benefit of therapeutic intervention. 
 During potent antiretroviral therapy, immune recovery is characterized 
by suppression of  HIV - 1 replication and increasing CD4+ T Cell count84. In 
our study group, the CD4 cell count improved by a mean of 205 cells / mm3.  
Control of HIV - 1 replication reduces CD4 T cell loss resulting from 
direct cytolysis85,86 and may partially restore T cell homeostasis by promoting 
decreased T cell proliferation87.88. Redistribution of T cells into peripheral 
circulation73,89 and improved thymic output90. Although many patients 
continue to have CD4 T cell recovery for several years after receiving 
HAART91, the degree of  immune recovery achieved during viral suppression 
is highly variable. In some individuals increases in the CD4 cell count appears 
to plateau  after the first few months of HAART92,93,94,95,96. This suboptimal 
CD4 T cell response during therapy otherwise  known as 'immunologic 
discordance' can have detrimental clinical consequences67. At present there is 
no validated or accepted, definition of immune discordance during HAART.   
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In general, reconstitution of CD4 T cells during viral suppression 
follows a biphasic pattern97. During the first three months of  HAART the 
number of CD4 T cells typically increase by 50 to 120 cells per mm3, 92,98,99. 
This burst is followed by a, second slower phase  of T cell repopulation with 
an average rate of increase of 2 to 7 cells mm3 per month92,98,99,100. 
In our study population, the CD4 count seems to have risen to a greater 
degree of about 205 cells / mm3, which could be both due to the smaller 
sample size but also could be because of the nutritional counselling that is 
given to our patients at the ART centre and also because of the 
supplementation of micro and macro nutrients and monthly monitoring of 
body weight and height.  
The  extent of  early immune recovery may be a function of  prior T 
cell destruction, because lower CD4 T cell  nadirs have been associated with 
limited immune recovery during therapy101. Furthermore because viral 
replication is incompletely suppressed by HAART102. In our study the patient 
on Group I and Group II showed a lesser increase when compared to Group 
III which showed the most statistically significant increase. This increase in 
Group III patients during HAART follow up showed a mean increase of 194 
cell / mm3, which when analysed for statistical significance by using paired 't' 
test showed a 'p' value of 0.000506, which is highly significant, in 
concordance with the previous studies. The intent of the present  study was to 
investigate the impact of HAART on CD4 count in a small prospective study.   
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In this study there were 58 patients with CD4 cell count of less than 
200 / µl, who were started on highly active antiretroviral therapy and followed 
up for 6 months. Of these 58 patients 17 patients had a CD4 count between 0-
99, who were classified a Group I, 16 patients had a CD4 cell count between 
100-150, who were classified as Group II and, 25 patients had a CD4 cell 
count between 150-199, who were classified as Group III. But, of these 58 
patients only 27 patients could be followed up for 6 months and a repeat CD4 
count could be done. These 27 patients' 6 month follow up CD4 count was 
analysed and it showed an improvement by a mean of 205 cells / mm3, which 
was also statistically significant when analysed by paired 't' test, that showed 
'p' value of 0.0000. When the groups were analyzed individually, the 3 groups 
of group I, group II, group III showed a 'p' value of 0.006, 0.008 and 0.0005 
respectively. But it is Group III, with the higher initial CD4 count of 150 – 
199 that showed the most statistically significant improvement when 
compared to the other two groups. When the improvement in BMI was 
assessed after 6 months by using paired 't' test it also showed a statistically 
significant improvement, with a 'P' value of 0.000660. From the study it is 
clear, when HAART is started, with the CD4 count at a higher level (Group 
III), the improvement in CD4 count as well as the general condition 
improvement is better.  
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CONCLUSION 
1. In this study there were 58 patients with CD4 cell count of less than 
200 / µl who were started on highly active antiretroviral therapy and 
followed up for six months. But only 27 patients came back after 6 
months of HAART, whose follow up CD4 count was done and 
analysed to evaluate the impact of HAART on CD4 cell count.  
2. It is important to do CD4 cell count in all the patients who are 
confirmed as HIV/AIDS, irrespective of the clinical stage, since the 
clinical stage and the CD4 count do not correlate.  
3. Patients were classified into three groups as per the initial CD4 cell 
count. (N = 27) 
 Initial  CD4 Cell Count No of  Patients followed 
up for 6 months 
Group I 0-99 8  
Group II 100-149 8 
Group III 150-199 11 
 Total 27 
 
4. These 27 patients 6 month follow up CD4 count was analysed and it 
showed an improvement by a mean of 205 cells / mm3 which was also 
statistically significant when analysed by using the paired 't' test, that 
showed a 'p' value of 0.0000. When the groups were analysed 
individually, the three groups of Group I, Group II, Group III, showed 
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a 'P' value of 0.006, 0.008, and 0.0005 respectively. Among these 3 
groups, it is group III, that showed the most statistically significant 
improvement. So HAART has a significant improvement on CD4 cell 
count when HAART is started with the CD4 count at a higher level as 
in Group III. 
5. HAART has improved the BMI and thereby improving the general 
condition and well being of the patients. This could also be attributed 
to the micronutrients and the macronutrients that were provided to the 
patients at the ART centre, KMCH.  
6. HAART decreases the incidence of opportunistic infections.  
7. Tuberculosis was the most common opportunistic infection. 
8. CD4 cell count monitoring is very important and could be done every  
3 months, but for resource constraints it is being done every 6 months.  
9. Limitation of the study: 
(a) small sample size, 
(b) four combinations of HAART regimens where used in these 27 
patients and the individual effect of each combination on CD4 
count was not evaluated. 
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PROFORMA 
 
Name :    Age :   Sex : 
 
Name of the Treatment Unit : 
 
Confirmed HIV Test Date : 
 
Risk factor for HIV  : 
 
1. Heterosexual 
2. IVDU 
3. Sex Work 
4. Men having sex with men 
5. Blood transfusion  
6. Mother to Child 
7. Unknown 
 
Smoker   : Yes / No 
Alcohol   : Yes / No 
 
 Height Weight CD4 Count Clinical Stage
Ist visit     
After 6 months 
during HAART 
    
 
HAART  Regimen : 
 
1. d4T30 + 3TC + NVP 
2. d4T40 + 3TC + NVP 
3. d4T30 + 3TC + EFV 
4. d4T40 + 3TC + EFV 
5. ZDV + 3TC + NVP 
6. ZDV + 3TC + EFV 
 
Associated Diseases / Illness  
 
1. Tuberculosis   
 
2. Jaundice 
 
3. Other Illness  
Pulmonary
Extra Pulmonary
ABBREVIATIONS 
 
 
AIDS  - Acquired  Immuno Deficiency Syndrome 
HIV  - Human Immuno Deficiency  Virus 
RNA  - Ribo Nucleic Acid 
PGL  - Persistent Generalised Lymphadenopathy 
HAART - Highly Active Anti retro Viral Therapy 
DC  - Dentritic Cell 
SIV  - Simian Immuno Deficiency Virus 
CTL  - Cytotoxic T Lymphocyte  
MHC  - Major Histocompatiblity Complex 
NK  - Natural Killer  
NACO - National Aids Control Organisation 
NNRTI - Non Nucleoside Reverse transcriptase Inhibitor 
CD  - Cluster of Differentiation  
ART  -  Anti retroviral Therapy 
USA  - United States of America 
 
